4/19
04:05 pm
acad
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/17
04:19 pm
acad
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
Low
Report
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting [Yahoo! Finance]
4/17
04:05 pm
acad
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
Low
Report
Acadia Pharmaceuticals Presents New DAYBUE™ (trofinetide) Clinical Data at the 2024 American Academy of Neurology (AAN) Annual Meeting
4/10
10:19 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $37.00 price target on the stock.
4/9
03:22 pm
acad
Taysha draws bullish view at Piper Sandler on lead asset [Seeking Alpha]
Low
Report
Taysha draws bullish view at Piper Sandler on lead asset [Seeking Alpha]
4/9
10:19 am
acad
Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 [Yahoo! Finance]
Low
Report
Rett syndrome - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report 2023 To 2033 [Yahoo! Finance]
4/9
08:09 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $32.00 price target on the stock.
4/5
07:00 am
acad
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
4/2
04:17 pm
acad
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development [Yahoo! Finance]
Low
Report
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development [Yahoo! Finance]
4/2
04:05 pm
acad
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
Low
Report
Acadia Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development
4/1
04:05 pm
acad
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Acadia Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference
4/1
07:00 am
acad
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
3/28
01:39 pm
acad
Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Acadia (ACAD) Down 23.4% Since Last Earnings Report? [Yahoo! Finance]
3/28
03:30 am
acad
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
3/26
12:00 pm
acad
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Acadia Pharmaceuticals Inc. (ACAD) Investigation
Low
Report
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Acadia Pharmaceuticals Inc. (ACAD) Investigation
3/26
03:30 am
acad
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
3/25
04:06 pm
acad
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/25
11:31 am
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $25.00. They now have an "overweight" rating on the stock.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $25.00. They now have an "overweight" rating on the stock.
3/25
04:30 am
acad
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
3/24
07:00 am
acad
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
3/22
07:00 am
acad
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
3/20
07:00 am
acad
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
3/19
03:30 am
acad
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
3/18
03:12 pm
acad
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Morgan Stanley from $40.00 to $30.00. They now have an "overweight" rating on the stock.
Low
Report
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) had its price target lowered by analysts at Morgan Stanley from $40.00 to $30.00. They now have an "overweight" rating on the stock.
3/18
03:30 am
acad
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm
Low
Report
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ACADIA Pharmaceuticals Inc. and Encourages Investors with Losses to Contact the Firm